The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Expected Market Size Of The Artificial Intelligence (AI) In Drug Discovery Market In 2026 And How Much Will It Reach By 2030?
The artificial intelligence (AI) in drug discovery market size has experienced significant expansion in recent years. It is forecast to increase from $2.33 billion in 2025 to $2.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 25.9%. The market’s past growth can be attributed to several factors, including escalating pharmaceutical R&D spending, the increasing complexity of drug discovery pipelines, greater availability of biological and chemical datasets, the early adoption of machine learning in bioinformatics, and growing collaboration between pharmaceutical and technology firms.
The artificial intelligence (AI) in drug discovery market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. The expansion during this forecast period is primarily driven by the increasing integration of generative AI models, a rising need for precision therapeutics, the broadening of AI-enabled clinical trial designs, expanding investments in cloud-based discovery platforms, and the regulatory acceptance of AI-assisted drug development. Noteworthy trends expected in the forecast period include a greater utilization of AI-driven target identification, increased adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the proliferation of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp
Which Core Factors Are Supporting The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?
The increasing need for personalized medicine is anticipated to fuel the expansion of artificial intelligence (AI) within the drug discovery market in the future. Personalized medicine represents a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s unique genetic, proteomic, or biological makeup to inform medical choices. The greater uptake of personalized medicine stems from the growing requirement for accurate, tailored therapies that enhance treatment outcomes and minimize side effects. AI facilitates this transition by speeding up the discovery of molecular targets, refining drug compounds, and improving clinical judgment across the entire development process. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based advocacy and research body, indicated that the U.S. FDA sanctioned 26 novel personalized treatments in 2023, comprising 20 new molecular entities and 6 gene- or cell-based therapies. Consequently, the expanding demand for personalized medicine is stimulating the advancement of artificial intelligence (AI) in the drug discovery market.
How Does Segment Analysis Break Down The Artificial Intelligence (AI) In Drug Discovery Market Structure?
The artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning
2) By Drug Type: Small Molecules, Large Molecules
3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics
4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis
3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications
What Trends Are Affecting The Artificial Intelligence (AI) In Drug Discovery Market Dynamics?
Leading corporations are allocating capital to firms leveraging artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and provide these methodologies to other pharmaceutical manufacturers. Such calculated investments offer financial support for the research and development phases of novel pharmaceuticals, an endeavor often characterized by high expenses and extended timelines. This financial backing enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. A notable example occurred in July 2023, when Nvidia, a US-based software firm, committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology enterprise utilizing artificial intelligence (AI) for drug discovery. This capital injection is intended to assist Recursion in speeding up the creation of its AI foundation models for biological and chemical applications, facilitated by leveraging Nvidia’s cloud infrastructure.
Who Are The Companies Shaping The Artificial Intelligence (AI) In Drug Discovery Market Landscape?
Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.
Access The Complete Artificial Intelligence (AI) In Drug Discovery Market Report:
Which Region Stands As The Largest Contributor To The Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Artificial Intelligence (AI) In Drug Discovery Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=3411&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company
Generative Artificial Intelligence Ai In Drug Discovery Global Market Report 2026
Artificial Intelligence Ai In Biopharmaceuticals Global Market Report 2026
Artificial Intelligence Ai In Predictive Toxicology Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model